Computational Models for new Patients Stratification Strategies of Neuromuscular Disorders
Acronym
CoMPaSS-NMD
Description of the granted funding
The CoMPaSS-NMD project creates novel and universal tools for the diagnostic stratification of patients suffering from Hereditary NeuroMuscular Diseases (HNMDs) aiming at personalised treatments.
HNMDs often occurs in young people, causing long-term disability and early death; these conditions bring lack of participation, need for permanent assistance and may require long-term institutionalisation.
Multidimensional HNMD data - clinical, genetic, histopathological and MRI – will be provided by third-level clinical centers in Italy, France, Germany, Finland and the United Kingdom as part of the European Reference Network for Rare Neurological Diseases. Computational tools for high-dimensional clustering will be applied in an unsupervised learning approach using the internal structure of data to define groups of similar patients. Classification model averaging and integration techniques for federated learning-inspired model building and novel HNMD-specific descriptors of histopathological images will be implemented.
The adoption of this multidimensional view has the potential to increment the diagnostic rate of HNMDs by 30% and foster effective actions by European national health systems.
As main project outcome, the CoMPaSS-NMD Atlas Platform will be a cost-effective AI-based application providing precise clinical characterization and diagnosis, with data remaining publicly available for anyone in the research and health community to use.
The project will deliver Recommendations and Guidelines for stratification-based patient management to offer superior standard-of-care for diagnosis and prognosis and assist in planning clinical trials. It will follow a user-centred, co-design methodology with a strong stakeholder engagement and networking with other project consortia.
The project engages partners with clinical, biotechnological, ICT, AI, ethical and legal, communication and exploitation competences: 6 clinical/academic centres, 1 academic, 4 industrial partners.
Show moreStarting year
2023
End year
2027
Granted funding
Samfundet Folkhälsan
380 890 €
Participant
FINCONS GROUP AG (CH)
Participant
CEGAT GMBH (DE)
507 500 €
Participant
KLINIKUM DER UNIVERSITAT MUNCHEN (DE)
842 666.25 €
Third party
Fondazione Stella Maris (IT)
478 625 €
Participant
DEEP BLUE SRL (IT)
433 875 €
Participant
FUNDACION TECNALIA RESEARCH & INNOVATION (ES)
608 020 €
Participant
UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA (IT)
653 750 €
Coordinator
POLITECHNIKA SLASKA (PL)
720 875 €
Participant
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE)
Participant
UNIVERSITY OF NEWCASTLE UPON TYNE (UK)
Participant
CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE (FR)
330 500 €
Participant
Amount granted
4 956 701 €
Funder
European Union
Funding instrument
HORIZON Research and Innovation Actions
Framework programme
Horizon Europe (HORIZON)
Call
Programme part
Health (11673 Tools, Technologies and Digital Solutions for Health and Care, including personalised medicine (11693 )
Topic
Computational models for new patient stratification strategies (HORIZON-HLTH-2022-TOOL-12-01-two-stageCall ID
HORIZON-HLTH-2022-TOOL-12-two-stage Other information
Funding decision number
101080874
Identified topics
brain, neuroscience